Navigation Links
Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Date:11/11/2011

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA.  

V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial evaluating CMX001 in transplant patients with BK virus (BKV) infection.  The poster presentation, entitled "CMX001 Was Well-Tolerated and Without Nephrotoxicity in Renal Transplant and Hematopoietic Stem Cell Transplant Recipients with BK Virus Infection in a Prospective, Randomized, Double-Blind Study," is part of the "Late-Breaking Clinical Trials Poster" session and begins at 10:00 am on Saturday, November 12 at the Philadelphia Convention Center.

"In the Phase 1/2 trial, CMX001 was generally safe and well tolerated when administered to renal transplant (RT) and hematopoietic stem cell transplant (HSCT) recipients," stated Wendy Painter, MD, MPH, Chief Medical Officer of Chimerix, Inc.  "Importantly, no signs of nephrotoxicity were seen following five weekly oral doses of 40 mg and the pharmacokinetics of CMX001 and cidofovir were similar between kidney transplant and bone marrow transplant recipients."  These findings are consistent with results from other CMX001 clinical trials and based on Chimerix's experience with subjects treated under emergency INDs.

CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, pre-emption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release.  Data from an ongoing, placebo-controlled Phase 2 clinical trial
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. Chimerix to Present at Upcoming Investor Conferences
11. Chimerix Initiates Phase 1 Study of CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Global ... developing innovative information technology solutions for patients, physicians, ... care stakeholders, announced today the signing of a ... Food and Drug Administration (FDA). This initiative ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... PITTSBURGH , Jan. 28 Today Carnegie Science ... sponsored by Eaton Corporation. , Carnegie Science Center established ... promote outstanding science and technology achievements in western Pennsylvania ... Awards have honored the accomplishments of more than 250 individuals ...
... , , TORONTO , Jan. ... biopharmaceutical company developing innovative immune-based biologics, today announced that ... of Directors as an independent director. Trillium Chairman Dr. ... pleasure to welcome such an experienced biotech executive as ...
... , , BEIJING , Jan. ... "Company"), a leading China -based vaccine manufacturer,announced today that it ... per common share. Sinovac has granted the underwriters a,30-day ... the same terms and conditions. This reflects an increase in ...
Cached Biology Technology:2010 Carnegie Science Awardees Announced 22010 Carnegie Science Awardees Announced 32010 Carnegie Science Awardees Announced 42010 Carnegie Science Awardees Announced 52010 Carnegie Science Awardees Announced 6Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors 2Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors 3Sinovac Announces Upsizing and Pricing of Common Share Offering 2Sinovac Announces Upsizing and Pricing of Common Share Offering 3
(Date:4/22/2014)... A team of nanotechnology researchers at the University of ... nanostructures and arrays using RNA. , The research, ... Endowed Chair in Nanobiotechnology at the UK College of ... article titled "RNA as a Boiling-Resistant Anionic Polymer Material ... coauthored by Emil F. Khisamutdinov and Daniel L. Jasinski. ...
(Date:4/22/2014)... As President Barack Obama begins a trip to ... strategic pivot to the Pacific, officials at the ... Asia-Pacific Technology and Education Partnership (APTEP) as an ... United States and its allies in the region. ... partnerships across the Asia-Pacific region, supports the development ...
(Date:4/22/2014)... another way of asking him or her to behave ... cells of the immune system tend to misbehave with ... these cells are known to misbehave similarly during spaceflight, ... cells to better understand how our immune systems change ... on Aging, part of the National Institutes of Health, ...
Breaking Biology News(10 mins):RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3For an immune cell, microgravity mimics aging 2For an immune cell, microgravity mimics aging 3For an immune cell, microgravity mimics aging 4For an immune cell, microgravity mimics aging 5
... New Haven, Conn.Yale University engineers have found that the ... cluster in the blood and stimulate the body,s natural ... article of the April 20 issue of the journal ... treatment used to boost the body,s ability to fight ...
... factors in tinnitus is low, according to new research from ... large population-based study to measure the heritability of tinnitus. ... what degree it is hereditary. Prevalence of tinnitus was 15.1 ... Tinnitus is a symptom with a variety of underlying ...
... fly around the world every day capturing images of ... days these satellites have provided visible and infrared imagery ... Iceland. Eyjafjallajkull is pronounced similar to "EYE-a-fyat-la-yu-goot," and ... eruptions are important sources of gases, such as sulphur ...
Cached Biology News:Carbon nanotubes boost cancer-fighting cells 22 NASA Satellites Capture Last 3 Days of Eyjafjallajokull's Ash Plume 2
... White lyophilized solid. PROTECT FROM LIGHT. ... inhibitor of γ-secretase. Equipotently inhibits the release ... = 2.6 μM) and Aβ x-42 ... HEK293 cells stably transfected with the Amyloid ...
...
Corticoliberin...
Microlite 2+ Plate, round bottom; an irradiated, high binding surface with enhanced dynamic range, extra high reflectivity and minimal cross talk for low signal luminescent reactions....
Biology Products: